{
  "source": "PA-Med-Nec-Reyvow.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2188-9\nProgram Prior Authorization/Medical Necessity\nMedication Reyvow® (lasmiditan)\nP&T Approval Date 3/2020, 7/2020, 2/2021, 7/2021, 3/2022, 10/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nReyvow (lasmiditan) is a serotonin 5-HT receptor agonist indicated for the acute treatment of\n1F\nmigraine with or without aura in adults. Sedation was reported up to 8 hours after a single dose\nof Reyvow. Patients should be advised to not engage in activities requiring complete mental\nalertness, such as driving a motor vehicle or operating machinery, for at least 8 hours after each\ndose of Reyvow.\nThe American Headache Society recommends use of NSAIDs (including aspirin), non-opioid\nanalgesics, acetaminophen, or caffeinated analgesic combinations (e.g.,\naspirin/acetaminophen/caffeine) for mild‐to‐moderate attacks and migraine‐specific agents\n(i.e.,triptans, dihydroergotamine [DHE]) for moderate or severe attacks and mild‐to‐moderate\nattacks that respond poorly to NSAIDs or caffeinated combinations.\nThis program requires a member to try lower cost options prior to receiving coverage for\nReyvow.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Reyvow will be approved based on all of the following criteria:\na. Used for acute treatment of migraine\n-AND-\nb. Patient is 18 years of age or older\n-AND-\nc. History of a therapeutic failure (after at least 3 migraine episodes and a minimum of a\n30-day trial), contraindication or intolerance to both of the following (document name\nand date tried):\n1) Two of the following:\n© 2025 UnitedHealthcare Services, Inc.\n1\na) almotriptan (Axert)\nb) eletriptan (Relpax)\nc) frovatriptan (Frova)\nd) naratriptan (Amerge)\ne) rizatriptan (Maxalt/Maxalt MLT)\nf) sumatriptan (Imitrex)\ng) zolmitriptan (Zomig/Zomig-ZMT)\n-AND-\n2) Both of the following:\na) Nurtec ODT\nb) Ubrelvy\n-AND-\nd. Prescriber attests to BOTH of the following:\n1) Patient has been informed the use of Reyvow",
    "Imitrex)\ng) zolmitriptan (Zomig/Zomig-ZMT)\n-AND-\n2) Both of the following:\na) Nurtec ODT\nb) Ubrelvy\n-AND-\nd. Prescriber attests to BOTH of the following:\n1) Patient has been informed the use of Reyvow may result in significant CNS\nimpairment, and may impact the patient’s ability to drive or operate machinery for\n8 hours after each dose\n2) If used concurrently with a benzodiazepine or other drugs that could potentially\ncause central nervous system (CNS) depression, the prescriber has acknowledged\nthat they have completed an assessment of increased risk for sedation and other\ncognitive and/or neuropsychiatric adverse events\n-AND-\ne. One of the following:\n1) Patient is currently treated with one of the following prophylactic therapies:\ni) A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\nii) Candesartan (Atacand)\niii) A calcitonin gene-related peptide receptor (CGRP) antagonist or inhibitor for\npreventive treatment of migraine [i.e., Aimovig (erenumab), Ajovy\n(fremanezumab)*, Emgality (galcanezumab), Qulipta, Vyepti (eptinezumab-\njjmr)^]\niv) Divalproex sodium (Depakote/Depakote ER)\nv) OnabotulinumtoxinA (Botox) [Note: Coverage of onabotulinumtoxinA\n(Botox) may be subject to additional benefit and coverage review\nrequirements]\nvi) a serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta),\nvenlafaxine (Effexor/Effexor XR)]\nvii) Topiramate (Topamax)\nviii) a tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]\n- OR –\n© 2025 UnitedHealthcare Services, Inc.\n2\n2) Patient has < 4 migraine days per month\n- OR –\n3) Patient has >/ = 4 migraine days per month and has contraindication or intolerance\nto one of the following prophylactic therapies:\ni) A beta-blocker (i.e., atenolol, metoprolol, nadolol, propranolol, or timolol)\nii) Candesartan (Atacand)\niii) A calcitonin gene-related peptide receptor (CGRP) antagonist or inhibitor for\npreventive treatment of migraine [i.e., Aimovig (erenumab), Ajovy\n(fremanezuma",
    " or timolol)\nii) Candesartan (Atacand)\niii) A calcitonin gene-related peptide receptor (CGRP) antagonist or inhibitor for\npreventive treatment of migraine [i.e., Aimovig (erenumab), Ajovy\n(fremanezumab)*, Emgality (galcanezumab), Qulipta, Vyepti (eptinezumab-\njjmr)^]\niv) Divalproex sodium (Depakote/Depakote ER)\nv) OnabotulinumtoxinA (Botox) [Note: Coverage of onabotulinumtoxinA\n(Botox) may be subject to additional benefit and coverage review\nrequirements]\nvi) a serotonin-norepinephrine reuptake inhibitor [i.e., duloxetine (Cymbalta),\nvenlafaxine (Effexor/Effexor XR)]\nvii) Topiramate (Topamax)\nviii) a tricyclic antidepressant [i.e., amitriptyline (Elavil), nortriptyline (Pamelor)]\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Reyvow will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n* Ajovy is typically excluded from coverage\n^Vyepti may be subject to additional benefit and coverage review requirements.\n3. Additional Clinical Programs:\n• Supply limits may apply.\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Reyvow [package insert]. Indianapolis, IN: Lilly USA, LLC,; September 2022.\n© 2025 UnitedHealthcare Services, Inc.\n3\n2. The American Headache Society Position Statement on Integrating New Migraine Treatments Into\nClinical Practice. AHS Consensus Statement. Headache. 2021; 61:1021-39.\n+\nProgram Prior Authorization/Medical Necessity – Reyvow\nChange Control\nDate Change\n3/2020 New program.\n7",
    "graine Treatments Into\nClinical Practice. AHS Consensus Statement. Headache. 2021; 61:1021-39.\n+\nProgram Prior Authorization/Medical Necessity – Reyvow\nChange Control\nDate Change\n3/2020 New program.\n7/2020 Updated requirement from three triptans to two triptans.\n2/2021 Removed moderate to severe migraine requirement. Added requirement\nfor < 4 migraines per month. Simplified criteria for >/= 4 migraines per\nmonth. Removed prescriber requirement from reauthorization criteria.\n7/2021 Updated the trial language to include 3 migraine episodes. Updated\nreferences.\n3/2022 Added a step through Nurtec ODT and Ubrelvy. Added the products\ntypically excluded from coverage. Added note for Vyetpi regarding\nadditional benefit and coverage review requirements. Updated references.\n3/2023 Annual review. Added Zomig-ZMT as a zolmitriptan example. Updated\nreferences.\n10/2023 Removed the “Routine Audit” language.\n3/2024 Annual review. No changes.\n3/2025 Annual review. Updated list of prophylactic agents and removed\nprescriber requirement.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}